贝伐单抗联合化疗治疗进展期非小细胞肺癌的现状与前景
摘要
贝伐单抗(bevacizumab)是抗血管内皮生长因子(VEGF)的单克隆抗体。研究证实,贝伐单抗联合治疗,能增加铂类为基础的双药化疗方案治疗进展期NSCLC的疗效。本文就贝伐单抗联合化疗治疗非小细胞肺癌的的研究进展作一综述。
出处
《西南军医》
2012年第2期330-332,共3页
Journal of Military Surgeon in Southwest China
参考文献25
-
1Yang L,Yang G,Zhou M,et al.Body mass index and mortality from lung cancer in smokers and nonsmokers:a nationally representative prospective study of220000men in China[J].Int J Cancer,2009,125(9):2136-2143. 被引量：1
-
2Jemal A,Siegel R,Xu J,Ward E.Cancer statistics,2010[J].CA Cancer J Clin,2010,60:277-300. 被引量：1
-
3Stinchcombe TE,Socinski MA.Current treatments for advanced stage non-small cell lung cancer[J].Proc Am Thorac Soc,2009,6(2):233-241. 被引量：1
-
4Schiller JH,Harrington D,Belani CP,Langer C,Sandler A,Krook J,Zhu J,Johnson DH.Comparison of four chemotherapy regimens for ad-vanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98. 被引量：1
-
5Hicklin DJ,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].Clin Oncol,2005,23(5):1011-1027. 被引量：1
-
6Jain RK.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J].Science,2005,307(5706):58-62. 被引量：1
-
7FDA approves Avastin in combination with chemotherapy for first-line treatment of most common type of lung cancer[J].Cancer Biol T-her,2006,5(11):1425-1428. 被引量：1
-
8Sandler A,Gray R,Perry MC,Brahmer J,Schiller JH,Dowlati A,Lilenbaum R,Johnson DH.Paclitaxel-carboplatin alone or with bev-acizumab for Non-Small-Cell Lung Cancer[J].N Engl J Med,2006,355(24):2542-2550. 被引量：1
-
9Dowlati A,Gray R,Sandler A,Schiller JH,Johnson DH.Cell adhesion molecules,vascular endothelial growth factor,and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study[J].Clin Cancer Res,2008,14(5):1407-1412. 被引量：1
-
10Reck M,von Pawel J,Zatloukal P,Ramlau R,Gorbounova V,Hirsh V,Leighl N,Mezger J,Archer V,Moore N,Manegold C.Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer:A-VAil[J].J Clin Oncol2009,27(8):1227-1234. 被引量：1
-
1杨四旬,谢蜀生.肿瘤基因治疗的现状与前景[J].科技导报,1993,11(2):36-39. 被引量：2
-
2夏海龙,姚程,易永林.PCR检测白血病和微小残留病的现状与前景[J].国外医学（输血及血液学分册）,1991,14(6):348-350.
-
3王敬慧,许国祥.非小细胞肺癌新辅助化疗及化放疗的现状与前景[J].结核病与胸部肿瘤,2003(4):353-361.
-
4周四维.浅表性膀胱癌规范化治疗现状与前景[J].现代泌尿外科杂志,2005,10(6):311-313. 被引量：13
-
5Kanz,L8,黄成龙.细胞因子联用的现状与前景[J].国外医学（军事医学分册）,1992,9(3):120-122.
-
6赵体平.肿瘤治疗的现状与前景[J].肿瘤,1990,10(6):281-283. 被引量：2
-
7龚镭,诸玲,胥明.胰腺癌基因治疗的现状与前景[J].胰腺病学,2005,5(1):56-57.
-
8陈龙邦,顾寿年.肿瘤生物治疗的现状与前景[J].医学研究生学报,1998,11(1):61-62. 被引量：1
-
9顾琴龙,刘逸菲.肿瘤基因治疗的产生、现状与前景[J].医学与哲学,1993,14(3):11-13. 被引量：1
-
10杨伟炎.从专题会看经鼻垂体瘤手术及颅底外科的现状与前景[J].中华耳鼻咽喉科杂志,1996,31(5):259-260.
